Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris



Press release





• Phyteneo, a specialty pharmaceutical company specialized in medical devices, will be in charge of CE mark registration and sales in Czech Republic.

• This first distribution partnership follows the positive results, announced on October 29, of the clinical study EXPL HPV-002 in cervical cancer detection.

• In Czech Republic it is estimated that among the 2.2 million of Pap test performed every year around 180,000 women are with a high risk-HPV.


Bagneux (France), November 22, 2018 – 6:00 pm CET- Genomic Vision (FR0011799907 – GV), a company specializing in the development of diagnostic tests for the early detection of cancers and hereditary diseases, and applications for life sciences research, today announced a licensing agreement with Phyteneo for the commercialization of the HPV integration test in Czech Republic with possibilities to extend this agreement to other countries of Central Eastern Europe.

Phyteneo will be in charge of the registration of the test as Medical Device to the regional regulatory agency (SUKL – State Institute for Drug Control). Once the test registered, Phyteneo will acquire a first molecular combing platform that will be installed in a key clinical center of the country.

Stéphane Altaba, Executive VP Corporate Development of GV, declared: “We were looking for a committed local partner with strong experience in registration and willing to launch the test in Czech Republic where the HPV integration test was appreciated by the doctors and the patients. With Phyteneo and Petr Behensky we have the right partner for making a success story in this pilot country”.

Petr Behensky, CEO of Phyteneo, added: ”We were very impressed by the first results of the EXPL-HPV-002  study and we believe that it will be a strong support to registration, and future launch of the product. The information provided by Genomic Vision test is completely new and gynecologists are very excited by the idea of having the possibility to propose to their patients a new test that could help them to optimize their follow up and care. We already know the centers that are willing to perform the test in Czech Republic and we are already thinking of making the test available for patients in other Eastern European Countries”.


This distribution partnership with Phyteneo just comes from the positive results of the clinical study EXPL-HPV-002 in cervical cancer detection on October 29, 2018. The collected data showed that the median value of HR-HPV virus integration in high grade patients is 3 times higher than in patient with no lesion.

In Czech Republic, 2.2 million screening procedures for cervical cancer (Pap Smear Test) are performed every year and around 180,000 women are detected with High risk-HPV.



GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing to identify genetic abnormalities, GENOMIC VISION stimulates the R&D productivity of the pharmaceutical companies, the leaders of the diagnostic industry and the research labs.

The Company develops a robust portfolio of diagnostic tests (breast, ovarian and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based near Paris, in Bagneux, the Company has approximately 50 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907). For further information, please visit:



Genomic Vision

Aaron Bensimon

Co-fondateur et Président du Directoire

Tél. : +33 1 49 08 07 50

Ulysse Communication

Press Relations

Bruno Arabian

Tel. : +33 1 42 68 29 70


Investor Relations & Strategic Communications

Tel. : +33 1 44 71 94 94




This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the  “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision ( and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.


This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.